About: Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus Infection
Creator	Ennis, Jane Russell, Andrew Turner, Jeffrey Wong, Min-Hui Gowen, Brian Sefing, Eric
Source	PMC
abstract	Several arenaviruses can cause viral hemorrhagic fever, a severe disease with case-fatality rates in hospitalized individuals ranging from 15-30%. Because of limited prophylaxis and treatment options, new medical countermeasures are needed for these viruses classified by the National Institutes of Allergy and Infectious Diseases (NIAID) as top priority biodefense Category A pathogens. Recombinant consensus interferon alpha (cIFN-α) is a licensed protein with broad clinical appeal. However, while cIFN-α has great therapeutic value, its utility for biodefense applications is hindered by its short in vivo half-life, mode and frequency of administration, and costly production. To address these limitations, we describe the use of DEF201, a replication-deficient adenovirus vector that drives the expression of cIFN-α, for pre- and post-exposure prophylaxis of acute arenaviral infection modeled in hamsters. Intranasal administration of DEF201 24 h prior to challenge with Pichindé virus (PICV) was highly effective at protecting animals from mortality and preventing viral replication and liver-associated disease. A significant protective effect was still observed with a single dosing of DEF201 given two weeks prior to PICV challenge. DEF201 was also efficacious when administered as a treatment 24 to 48 h post-virus exposure. The protective effect of DEF201 was largely attributed to the expression of cIFN-α, as dosing with a control empty vector adenovirus did not protect hamsters from lethal PICV challenge. Effective countermeasures that are highly stable, easily administered, and elicit long lasting protective immunity are much needed for arena and other viral infections. The DEF201 technology has the potential to address all of these issues and may serve as a broad-spectrum antiviral to enhance host defense against a number of viral pathogens.
has issue date	2011-10-24(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0026072
bibo:pmid	22039436
has license	cc-by
sha1sum (hex)	c1df508d29e27cafd7a54a39bc2e087caa3a6bc6
schema:url	https://doi.org/10.1371/journal.pone.0026072
resource representing a document's title	Use of Recombinant Adenovirus Vectored Consensus IFN-α to Avert Severe Arenavirus Infection
has PubMed Central identifier	PMC3200317
has PubMed identifier	22039436
schema:publication	PLoS One
resource representing a document's body	covid:c1df508d29e27cafd7a54a39bc2e087caa3a6bc6#body_text
is schema:about of	named entity 'USE OF' named entity 'immunity' named entity 'Ennis' named entity 'Russell' named entity 'efficacious' named entity 'hospitalized' named entity 'Adenovirus' named entity 'IFN-a' named entity 'MEDICAL COUNTERMEASURES' named entity 'MODE' named entity 'SINGLE' named entity 'VALUE' named entity 'GIVEN' named entity 'RECOMBINANT ADENOVIRUS' named entity 'IFN-A' named entity 'ARENAVIRUSES' named entity 'POST' named entity 'DRIVES' named entity 'HIGHLY' named entity 'MUCH' named entity 'EXPOSURE' named entity 'HOST DEFENSE' named entity 'ENHANCE' named entity 'GREAT' named entity 'BROAD' named entity 'INSTITUTES' named entity 'PATHOGENS' named entity 'ISSUES' named entity 'IN VIVO' named entity 'INTRANASAL ADMINISTRATION' named entity 'NEEDED' named entity 'OBSERVED' named entity 'CLASSIFIED' named entity 'ADMINISTERED' named entity 'NATIONAL' named entity 'UTILITY' named entity 'POTENTIAL' named entity 'PROTECTIVE EFFECT' named entity 'HALF-LIFE' named entity 'CATEGORY' named entity 'CAUSE' named entity 'ADMINISTRATION' named entity 'LIMITATIONS' named entity 'INFECTIOUS DISEASES' named entity 'LONG' named entity 'HAMSTERS' named entity 'SHORT' named entity 'PRIORITY' named entity 'CHALLENGE' named entity 'VECTOR' named entity 'ASSOCIATED' named entity 'SEVERE DISEASE' named entity '30%' named entity 'POST-EXPOSURE PROPHYLAXIS' named entity 'ADENOVIRUS' named entity 'VIRAL PATHOGENS' named entity 'SPECTRUM' named entity 'RECOMBINANT CONSENSUS INTERFERON' named entity 'DESCRIBE' named entity 'LARGELY' named entity 'EFFECTIVE' named entity 'FREQUENCY' named entity 'ITS' named entity 'VIRUS' named entity 'WONG' named entity 'THERAPEUTIC' named entity 'EXPRESSION' named entity 'DISEASE' named entity 'CLINICAL' named entity 'STABLE' named entity 'PROTECTIVE IMMUNITY' named entity 'PRODUCTION' named entity 'LIMITED' named entity 'TECHNOLOGY' named entity 'PREVENTING' named entity 'NEW'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software